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Abstract
A cyclosporine (CsA)-based immunosuppression is as-
sociated with an increased incidence of cholelithiasis
after heart transplantation. It is not known if tacro-
limus (Tac) has comparable biliary side effects in hu-
mans.
We evaluated the incidence of gallbladder sludge
and cholelithiasis under Tac-based immunosuppres-
sion by ultrasound examinations in 31 cardiac trans-
plants (25 male, 6 female, mean age: 59 ﾱ 11 years).
Data were compared to 57 patients (47 male, 10 fe-
male, mean age: 58 ﾱ 11 years) who received CsA-
based immunosuppression.
6 patients receiving Tac and 6 patients receiving
CsA had already gallstones prior to transplantation so
that finally 25 patients of the Tac group and 51 pa-
tients of the CsA group could be evaluated.
In the Tac group the incidence of biliary sludge was
4% (1 of 25), of gallstones 28% (7 of 25). In compari-
son, patients receiving CsA developed biliary sludge in
also 4% (2 of 51) and gallstones in 25% (13 of 51).
Nine of 42 males in the CsA group (21%) and eight of
20 males in the Tac group (40%) developed either gall-
stones or sludge (n.s). Six of nine females in the CsA
group (67%), but none of five females in the Tac
group (0%) developed either gallstones or sludge (p =
0.01).
In summary, the incidence of biliary disease in pa-
tients with Tac is comparable with CsA-based im-
munosuppression. We recommend regular sonograph-
ical examinations to detect biliary diseases as early as
possible. In cases of clinically, laboratory and sono-
graphical signs of cholecystitis cholecystectomy is in-
dicated. It seems that towards lithogenicity female pa-
tients benefit more from a Tac-based treatment be-
cause the occurrence of gallstones is rare.
INTRODUCTION
Cyclosporine A (CsA), a calcineurin phosphatase in-
hibitor is a widely used immunosuppressive agent af-
ter heart transplantation (HTx). CsA is metabolized in
the liver and excreted predominantly via biliary secre-
tion, which results in an impaired biliary excretion of
bile salts and therefore in cholestasis. In heart trans-
plants a high incidence of cholelithiasis is observed in
up to 35% of the patients [1]. The specific mecha-
nisms for lithogenesis using CsA treatment have not
been definitively elucidated, but various pathophysio-
logical mechanisms have been discussed. Previous
studies revealed an inhibition of ATP-dependent ex-
port carriers for bile salts, especially taurocholate and
cysteinyl leukotriens in the hepatocyte canalicular
membrane shown in liver plasma membrane vesicles
of rats [2] as well as of humans [3]. Another study in
rats has shown a decreased bile salt synthesis and
secretion combined with an unchanged cholesterol se-
cretion, which leads to an elevated cholesterol satura-
tion of bile and consequently in gallstones [4]. How-
ever, Chanussot and co-workers found only a tran-
sient intrahepatic cholestasis in rats [5]. Galan and co-
workers described an altering in liver plasma mem-
brane composition, fluidity and function, as well as an
induction of oxidative stress and depletion of hepatic
glutathione and proteins, which might cause cholesta-
sis [6].
It is not known if tacrolimus (Tac), a new cal-
cineurin phosphatase inhibitor which improved the
results of organ transplantation [7] has comparable
biliary side effects like CsA in heart transplanted pa-
tients. The metabolism of Tac is similar to CsA, both
drugs bind to immunophilins, afterwards the active re-
ceptor-drug-complex inhibits the enzyme calcineurin
phosphatase [8]. Only a few studies exist in humans
beyond potential cholestatic effects of Tac. Cao and
co-workers stated that Tac may be warranted to pre-
vent biliary morbidity based on a case report of a
young liver transplanted patient. In a rat model, Mizu-
ta and co-workers showed cholestatic effects of CsA
including reduced bile flow and bile acid secretion,
whereas Tac increased bile secretion with little influ-
ence on bile flow. Due to data of a later study they
suggested that Tac in high doses might induce
cholestasis by inhibiting bile acid secretion relatively
[9, 10]. Furthermore Tac applied in high doses in-
duced cholestasis by inhibiting the biliary glutathione
secretion [11].
The aim of this study was to evaluate the incidence
and possible risk factors of gallbladder sludge and
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with Tac- versus CsA-based immunosuppressive treat-
ment. Further we studied the incidence of sympto-
matic cholelithiasis and the outcome of patients which
required surgery.
METHODS
PATIENTS
31 heart transplant recipients (25 male, 6 female, mean
age 59 ﾱ 11 years, mean follow up 5 ﾱ 2.5 years) with
Tac-based immunosuppressive therapy were compared
with 57 heart transplant recipients (47 male, 10 female,
mean age 58 ﾱ 11 years, mean follow up 11 ﾱ 4.6
years) with a CsA-based immunosuppression. These
both groups came from two different transplantation
eras, the CsA group from 1985 to 2000, and the Tac
group from 1993 to 2001. Patients were not random-
ized to one of these groups. The definite follow-up in-
vestigation was performed five years after transplanta-
tion, respectively. Body mass index (BMI), age, hyper-
lipidaemia, diabetes mellitus as well as laboratory para-
meters of liver-condition were also analysed to detect
other risk factors of biliary disease. Patients with re-
current colics localized in the upper right-sided ab-
dominal quadrant were considered as symptomatic.
ABDOMINAL ULTRASONOGRAPHY
Ultrasonography was performed prior to transplanta-
tion and annually after transplantation using a 3.5
MHZ convex-array scanner (Siemens Sonoline Elegra,
Erlangen, Germany) to detect biliary disease. The gall-
bladder was examined in intercostal and subcostal
scans. Intraluminal findings were characterized as
sludge (echogenic sedimentation) or gallstones (hyper-
echogenic reflexes with posterior acoustical shadow).
BIOCHEMICAL ANALYSES
Blood samples were taken at 2-3 week intervals for de-
termination of Tac and CsA blood levels. Initially the
CsA level acquired by monoclonal monospecific im-
munoassay, amounted to 160-180 ng/ml. After 6
months the CsA dosage could be reduced to reach
serum levels between 100-120 ng/ml. The corticos-
teroid dosage amounted initially to 7.5 mg/die and
had been lowered over a period of 1-2 years to 5
mg/die. In addition to corticosteroids, combination
therapy included a purinanalogon [either azathioprine
(AZA 50-75mg/die),or mycophenolate mofetil (MMF:
serum levels in the first 1/2 year 2.0-4.5 ﾵg/ml, later
1.5-3 ﾵg/ml)]. Since 1993 a Tac-based immunosup-
pressive therapy was introduced instead of a CsA-
based treatment. The Tac level investigated by ra-
dioimmuno assay (RIA) amounted 12-16 ng/ml in the
first 6- months after HTx, later 8-10 ng/ml. The MMF
level in this combination accounted 1.5-3 ﾵg/ml.
Other laboratory measurements included serum
glutamic pyruvate transaminase (SGPT), serum glu-
tamic oxaloacetic transaminase (SGOT), γ-glutamyl
transferase (γ-GT), alcaline phosphatase (AP) and total
serum bilirubine as markers of hepatotoxicity (Hitachi
917 Boehringer, Mannheim, Germany).
STATISTICAL ANALYSES
All data were expressed as mean ﾱ SD. Statistics were
computed using Student’s t-test for normally distrib-
uted data and Whitney-Mann U tests for non-normally
distributed data. For all tests, a two-tailed P value of
less than 0.05 was considered significant. Statistical
analyses were performed using SigmaStat 3.0 for Win-
dows 2000. The ethical review board of the Ludwig-
Maximilians University Munich approved the study.
Written informed consent for participation was ob-
tained from all subjects.
RESULTS
Table 1 shows the baseline demographic and blood
chemical characteristics of 76 heart transplanted pa-
tients divided in those receiving tacrolimus (n = 25)
and those receiving cyclosporin A (n = 51). There was
no significant difference between the study groups
with regard to age, BMI, SGOT, SGPT, AP, γ-GT and
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Table 1. Demographic characteristics and laboratory parameters of 76 heart transplanted patients divided in two groups receiv-
ing either tacrolimus or cyclosporin A as basic immunosuppressive drug.
Tacrolimus Cyclosporin A Significance
n=25 n = 51 (p-value)
Age 57 ﾱ 11.5 57 ﾱ 10.8 n.s.
Male/female (n) 20/5 42/9 n.s.
BMI 26.0 ﾱ 4.3 27.3 ﾱ 7.2 n.s.
SGOT (< 40 U/l) 21.7 ﾱ 7.9 21.3 ﾱ 8.5 n.s.
SGPT (< 45 U/l) 18.4 ﾱ 8.0 17.1 ﾱ 8.4 n.s
AP (< 135 U/l) 73.7 ﾱ 15.5 87.7 ﾱ 25.6 n.s
g-GT (< 55 U/l) 42.3 ﾱ 40.3 49.7 ﾱ 45.1 n.s
Bilirubine (< 1.0 mg/dl) 0.67 ﾱ 0.29 0.88 ﾱ 0.54 n.s
Diabetes mellitus (n) 88 n.s
Hyperlipidaemia (n) 11 34 n.s
BMI: body mass index, SGOT: serum glutamec oxalacetic transaminase, SGPT: serum glutamic pyruvate transaminase, g-GT: g-
glutamyl transferase
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lipidaemia.
6 patients (19%) receiving Tac and 6 patients (10%)
receiving CsA had already gallstones prior to trans-
plantation so that finally 25 patients of the Tac group
and 51 patients of the CsA group could be evaluated
for the incidence of biliary diseases for at least five
years after cardiac transplantation (Table 2).
The annual serial abdominal ultrasound examina-
tion after HTx showed an gallstone- incidence in 13
patients under CsA treatment (25%) and in seven pa-
tients under Tac treatment (28%). Sludge was detected
in two patients receiving CsA and in one patient re-
ceiving Tac (4%, respectively).
Regarding gender, nine of the CsA treated male pa-
tients (21%) had either gallstones or sludge compared
to eight male patients in the Tac group (40%). Among
female patients six developed gallstones or sludge in
the CsA group (67%), but none in the Tac group (0%),
which was significantly different (p = 0.01).
Cholecystectomy was performed in two sympto-
matic patients receiving CsA (4%) and in one patient
treated with Tac (4%). All symptomatic patients were
operated via laparoscopic cholecystectomy. Complica-
tions were not seen in this population after surgery
and hospitalization time was not elongated.
DISCUSSION
Although there are numerous data about the lithogen-
ic characteristics of a CsA-based immunosuppressive
therapy in animal studies [2, 4-6, 12-14], as well as in
transplanted patients [1, 15], clinical studies of hepato-
biliary complications using Tac, which is similarly me-
tabolized like CsA, are rare. Most animal model studies
showed no or only mild lithogenic effects of Tac com-
pared with CsA [16, 17]. In contrast, Kawamura and
co-workers showed even a significant increase in bile
flow under Tac, whereas CsA treatment resulted in a
significant decrease of bile flow in rats [18].
Our study revealed overall a high incidence of
cholelithiasis in heart-transplanted patients with up to
28% compared with healthy persons which is some-
what higher than in other studies [19, 20], but in ac-
cordance to prevalence data of our own study on kid-
ney/pancreas-transplanted type 1 (insulin-dependent)
diabetic patients [21]. Among these heart-transplanted
patients the incidence of cholelithiasis or sludge be-
tween Tac- versus CsA-based immunosuppressive
treatment was nearly the same. Obviously, the findings
of previous animal studies do not lead to clinically rel-
evant different effects in humans.
All relevant laboratory analyses were similar in both
groups and also in normal ranges.
Interestingly, some gender-depending observations
were obvious. Under a Tac-based treatment, gallstones
or sludge occurred exclusively in male patients, where-
as in none of the female patients which was a signici-
cant difference. In contrast, under a CsA-based thera-
py percentually more female patients developed gall-
stones or sludge than male patients (67 vs. 21 %). So
far we have no explantation for this finding.
Only a minority of our patients with gallstones be-
came symptomatic and required surgery (6% CsA, 4%
Tac). All affected transplanted patients underwent la-
paroscopical surgery without any complications like
sepsis or peritonitis so that no prolonged hospitaliza-
tions were necessary. No cholecystitis was missed. Sev-
eral studies described a high postoperative complica-
tion rate in cases of acute cholecystitis in transplanted
patients with the suggestion to perform prophylactic
laparoscopic cholecystectomy prior to or post trans-
plantation in patients with gallstones [15, 22-24].
However, Steck and co-workers described only a mi-
nority of symptomatic heart transplanted patients with
cholelithiasis which is the basis of our conservative
procedure [25].
We conclude that due to the lithogenic effects of
CsA and Tac serial abdominal ultrasonography of the
gallbladder and regular controls of biochemical para-
meters of cholestasis are important to be aware of po-
tential biliary complications. In cases of clinically, lab-
oratory and sonographical signs of cholecystitis chole-
cystectomy is indicated. It seems that towards the lith-
ogenicity female patients benefit more from a Tac-
based treatment because the occurrence of gallstones
is rare.
Acknowledgement: This study was supported by grants of the
Friedrich-Baur-Stiftung (Munich).
EUROPEAN JOURNAL OF MEDICAL RESEARCH 208 May 14, 2009
Table 2. Incidence of gallstones/sludge in 76 heart transplanted patients divided in two groups receiving either tacrolimus or cy-
closporin A as immunosuppression
Tacrolimus Cyclosporin A Significance
n = 25 n = 51 Tac vs. CsA
(p-value)
Male/female (n) 20/5 42/9
Gallstones (%) 7 (28) 13 (25) n.s
Sludge ( %) 1 (4) 2 (4) n.s.
Males with either 8 (40) 9 (21) n.s.
gallst. or sludge (%)
Females with either 0 (0) 6 (67) 0.01
gallst. or sludge (%)
Surgery 1 2 n.s.
Postop. complications 00 n.s.
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